格隆汇3月7日丨华海药业(600521.SH)公布，截至2023年3月7日，公司股价已出现任意三十个连续交易日中至少十五个交易日收盘价格低于当期转股价格的80%之情形，触及“华海转债”转股价格向下修正条款。
经公司第八届董事会第十一次临时会议审议通过，公司董事会决议此次不行使“华海转债”转股价格向下修正的权利，且在未来2个月内(2023年3月8日至2023年5月7日)，如再次触及可转债的转股价格向下修正条款，亦不提出向下修正方案。从2023年5月8日开始重新起算，若再次触发“华海转债”的转股价格向下修正条款，届时公司董事会将再次召开会议决定是否行使“华海转债”的转股价格向下修正权利。
Risk disclosure: The above content only represents the opinion of the authors or guests, and does not represent any positions of Futu or constitute any investment advice on the part of Futu. Before making any investment decision, investors should consider the risk factors related to investment products based on their own circumstances and consult professional investment advisers where necessary. Futu makes every effort to verify the authenticity, accuracy, and originality of the above content, but does not make any guarantees or promises.
